Viatris stock price moved to $11.31, reflecting mild buying interest ahead of anticipated Q3 earnings guidance revisions. Viatris Inc. (NASDAQ:VTRS) has more than 250 products in development or regulatory review, including sophisticated generics and therapies for conditions with few other options. It stands out for its ability to maximize its product portfolio and generate value through its robust drug pipeline. Shares of the drug manufacturer have underperformed the broader market over the past year. VTRS stock has tanked 28.3% over the past 52 weeks and 31.9% on a YTD basis. In comparison, the S&P 500 Index ( $SPX ) has returned 8.2% over the past year but has dropped 4.7% in 2025. Viatris stock price touched $11.34, with trading algorithms picking up momentum signals tied to healthcare index strength over the last five sessions.